BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
ZBTB7A
,
Angiogenesis
,
Inflammatory disorder
,
Heart
,
Hematopoietic cell
,
Doxorubicin
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
122-85-0
Summary
General Info
Curated Studies
Most Correlated Studies
There were no matches for 122-85-0
Explore Curated Studies Results
Literature
Most Relevant Literature
Comparison of surgical and patient-reported outcomes between 85 profunda artery perforator flaps and…
High expression levels of circulating microRNA-122 and microRNA-222 are associated with obesity in c…
Circulating MicroRNA-122 for the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis.
Real-life results in treating neovascular age-related macular degeneration with anti-VEGF therapy. A…
Diagnostic Performance of microRNA-122 and microRNA-224 in Hepatitis C Virus-Induced Hepatocellular …
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis
Liver Test Study of Using JKB-122 in HCV-Positive Patients
Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertensi…
Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 t…
A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Act…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ